SG11201908475RA - Process for making hepatitis b core protein modulators - Google Patents
Process for making hepatitis b core protein modulatorsInfo
- Publication number
- SG11201908475RA SG11201908475RA SG11201908475RA SG11201908475RA SG 11201908475R A SG11201908475R A SG 11201908475RA SG 11201908475R A SG11201908475R A SG 11201908475RA SG 11201908475R A SG11201908475R A SG 11201908475RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- pct
- hepatitis
- carmel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/02—Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
- C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762470560P | 2017-03-13 | 2017-03-13 | |
| PCT/US2018/022100 WO2018169907A1 (en) | 2017-03-13 | 2018-03-13 | Process for making hepatitis b core protein modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908475RA true SG11201908475RA (en) | 2019-10-30 |
Family
ID=61768549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908475R SG11201908475RA (en) | 2017-03-13 | 2018-03-13 | Process for making hepatitis b core protein modulators |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11040965B2 (https=) |
| EP (1) | EP3596070A1 (https=) |
| JP (1) | JP7179751B2 (https=) |
| KR (1) | KR102575605B1 (https=) |
| CN (1) | CN110612300B (https=) |
| AU (1) | AU2018236188B2 (https=) |
| CA (1) | CA3056696A1 (https=) |
| SG (1) | SG11201908475RA (https=) |
| WO (1) | WO2018169907A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017326356A1 (en) | 2016-09-15 | 2019-04-11 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
| CA3055194A1 (en) | 2017-03-02 | 2018-09-07 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
| BR112021023622A2 (pt) * | 2019-05-24 | 2022-04-19 | Assembly Biosciences Inc | Composições farmaceuticas para o tratamento de hbv |
| CN111333513B (zh) * | 2020-04-17 | 2021-08-27 | 江苏恒沛药物科技有限公司 | 一种2,4-二氟-3-硝基苯甲酸的制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1480553A (en) | 1976-06-03 | 1977-07-20 | Pfizer Ltd | Tricyclic sulphonamides |
| JPS58225074A (ja) | 1982-06-25 | 1983-12-27 | Chugai Pharmaceut Co Ltd | ジベンゾオキサゼピン誘導体 |
| GB9109557D0 (en) | 1991-05-02 | 1991-06-26 | Wellcome Found | Chemical compounds |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| GB9707695D0 (en) * | 1996-08-07 | 1997-06-04 | Hoffmann La Roche | Tricyclic dione derivatives |
| US20050192286A1 (en) * | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| DE102004004928A1 (de) | 2004-01-31 | 2005-08-18 | Bayer Healthcare Ag | Dibenzoxazepine II |
| WO2007047737A1 (en) | 2005-10-17 | 2007-04-26 | Acadia Pharmaceuticals Inc. | Cb-1 modulating compounds and their use |
| WO2007056388A2 (en) | 2005-11-07 | 2007-05-18 | The General Hospital Corporation | Compositions and methods for modulating poly (adp-ribose) polymerase activity |
| JP4042065B1 (ja) | 2006-03-10 | 2008-02-06 | 健治 吉田 | 情報処理装置への入力処理システム |
| US20100022509A1 (en) | 2006-06-07 | 2010-01-28 | Fahey Robert C | Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same |
| WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| AU2009274255A1 (en) | 2008-07-23 | 2010-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the plasmodial surface anion channel as antimalarials |
| WO2012045194A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| JP5977347B2 (ja) | 2011-07-01 | 2016-08-24 | バルーク エス．ブルームバーグ インスティテュート | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| US20150141384A1 (en) * | 2012-07-03 | 2015-05-21 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
| RU2519546C1 (ru) | 2013-01-16 | 2014-06-10 | Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| EP3943087A1 (en) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| US9550742B2 (en) * | 2013-07-29 | 2017-01-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 11-OXO-10,11-dihydrodibenzo[B,F][1,4]thiazepine S-oxide derivatives and their use as dopamine D2 receptor antagonists |
| CN104803880B (zh) * | 2014-01-23 | 2017-11-21 | 广州喜鹊医药有限公司 | 一种具有神经保护作用的化合物及其制备方法和应用 |
| ES2748029T3 (es) | 2014-03-13 | 2020-03-12 | Univ Indiana Res & Tech Corp | Moduladores alostéricos de proteína núcleo de hepatitis B |
| PL3154949T3 (pl) | 2014-06-10 | 2018-08-31 | Basf Se | PODSTAWIONE ZWIĄZKI [1,2,4]TRIAZOLOWE i IMIDAZOLOWE JAKO FUNGICYDY |
| TWI721016B (zh) * | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| AU2017326356A1 (en) * | 2016-09-15 | 2019-04-11 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
-
2018
- 2018-03-13 AU AU2018236188A patent/AU2018236188B2/en not_active Ceased
- 2018-03-13 CA CA3056696A patent/CA3056696A1/en active Pending
- 2018-03-13 EP EP18713555.3A patent/EP3596070A1/en not_active Withdrawn
- 2018-03-13 SG SG11201908475R patent/SG11201908475RA/en unknown
- 2018-03-13 KR KR1020197029525A patent/KR102575605B1/ko active Active
- 2018-03-13 WO PCT/US2018/022100 patent/WO2018169907A1/en not_active Ceased
- 2018-03-13 JP JP2019550235A patent/JP7179751B2/ja active Active
- 2018-03-13 US US16/493,614 patent/US11040965B2/en not_active Expired - Fee Related
- 2018-03-13 CN CN201880030078.4A patent/CN110612300B/zh not_active Expired - Fee Related
-
2021
- 2021-01-14 US US17/149,485 patent/US20210380577A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3056696A1 (en) | 2019-09-20 |
| CN110612300A (zh) | 2019-12-24 |
| KR102575605B1 (ko) | 2023-09-05 |
| JP2020510059A (ja) | 2020-04-02 |
| US11040965B2 (en) | 2021-06-22 |
| WO2018169907A1 (en) | 2018-09-20 |
| JP7179751B2 (ja) | 2022-11-29 |
| EP3596070A1 (en) | 2020-01-22 |
| US20210380577A1 (en) | 2021-12-09 |
| US20200002325A1 (en) | 2020-01-02 |
| CN110612300B (zh) | 2023-10-20 |
| AU2018236188A1 (en) | 2019-10-17 |
| AU2018236188B2 (en) | 2022-01-27 |
| KR20190128675A (ko) | 2019-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901959YA (en) | Modified stem cell memory t cells, methods of making and methods of using same | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201908012SA (en) | Cyclic sulfamide compounds and methods of using same | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201810522UA (en) | Anti-cd40 antibodies and their uses | |
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
| SG11201908475RA (en) | Process for making hepatitis b core protein modulators | |
| SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
| SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| SG11201810123SA (en) | Treatment of intrahepatic cholestatic diseases |